抗血管生成-话题@MedSci

#抗血管生成#

32篇内容 | 2200人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1545649, encodeId=9cdb1545649f6, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168217, objectId=b3e216821e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3e216821e12, replyNumber=0, likeNumber=98, createdTime=2019-06-14, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3e216821e12, moduleTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3e216821e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545648, encodeId=1d591545648ff, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168100, objectId=14f816810048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f816810048, replyNumber=0, likeNumber=79, createdTime=2019-06-12, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f816810048, moduleTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f816810048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545647, encodeId=4d1b154564e0a, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=Biomaterials：研发基于高分子铜螯合剂的多功能纳米治疗体系用于联合抗血管生成与免疫疗法靶向治疗乳腺癌, objectType=article, longId=164188, objectId=ac4916418853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac4916418853, replyNumber=0, likeNumber=73, createdTime=2019-04-15, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac4916418853, moduleTitle=Biomaterials：研发基于高分子铜螯合剂的多功能纳米治疗体系用于联合抗血管生成与免疫疗法靶向治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac4916418853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545646, encodeId=d38c1545646fe, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, objectType=article, longId=156533, objectId=8846156533e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8846156533e5, replyNumber=0, likeNumber=107, createdTime=2018-12-25, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8846156533e5, moduleTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8846156533e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545645, encodeId=2dfe154564566, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=Gene & Cancer Sci：【重磅】盐酸安罗替尼抗血管生成机制详解, objectType=article, longId=134227, objectId=012513422ed4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012513422ed4, replyNumber=0, likeNumber=72, createdTime=2018-04-05, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012513422ed4, moduleTitle=Gene & Cancer Sci：【重磅】盐酸安罗替尼抗血管生成机制详解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012513422ed4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545644, encodeId=ed471545644f8, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=【大咖来啰】抗血管生成新药安罗替尼崭露锋芒, objectType=article, longId=121660, objectId=accd1216603f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=accd1216603f, replyNumber=0, likeNumber=74, createdTime=2017-11-30, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=accd1216603f, moduleTitle=【大咖来啰】抗血管生成新药安罗替尼崭露锋芒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=accd1216603f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545643, encodeId=212a1545643bf, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=ANN ONCOL：FAK蛋白表达与结直肠癌抗血管生成治疗反应有关, objectType=article, longId=118275, objectId=827d1182e556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=827d1182e556, replyNumber=0, likeNumber=64, createdTime=2017-11-02, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=827d1182e556, moduleTitle=ANN ONCOL：FAK蛋白表达与结直肠癌抗血管生成治疗反应有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=827d1182e556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=Front Mol Neurosci：研究发现抗血管生成的通路或可成为成胶质细胞瘤的新靶点, objectType=article, longId=117072, objectId=c52811e072b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c52811e072b2, replyNumber=0, likeNumber=71, createdTime=2017-10-23, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c52811e072b2, moduleTitle=Front Mol Neurosci：研究发现抗血管生成的通路或可成为成胶质细胞瘤的新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c52811e072b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545641, encodeId=a6041545641dc, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=【CSCO 2017】王宝成教授：抗血管生成治疗耐药的理解与对策, objectType=article, longId=114967, objectId=215f11496e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=215f11496e1b, replyNumber=0, likeNumber=58, createdTime=2017-10-02, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=215f11496e1b, moduleTitle=【CSCO 2017】王宝成教授：抗血管生成治疗耐药的理解与对策, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=215f11496e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545640, encodeId=14971545640cb, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识（2016年版）, objectType=article, longId=83667, objectId=9ab08366e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab08366e23, replyNumber=0, likeNumber=71, createdTime=2016-12-08, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab08366e23, moduleTitle=晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识（2016年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab08366e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545639, encodeId=69c91545639da, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=PNAS：抗血管生成药物可显著改善肺结核的治疗, objectType=article, longId=46606, objectId=4ad14660638, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad14660638, replyNumber=0, likeNumber=62, createdTime=2015-02-05, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad14660638, moduleTitle=PNAS：抗血管生成药物可显著改善肺结核的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ad14660638)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545638, encodeId=bbc9154563860, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=Int J Cancer：抗血管生成药物多巴胺或可用于癌症治疗, objectType=article, longId=45331, objectId=fc7f4533128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc7f4533128, replyNumber=0, likeNumber=85, createdTime=2015-01-14, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc7f4533128, moduleTitle=Int J Cancer：抗血管生成药物多巴胺或可用于癌症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc7f4533128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545637, encodeId=ccdf154563e9b, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=Nature：抗血管生成药物治疗癌症的局限性, objectType=article, longId=5000, objectId=2cff5000a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cff5000a3, replyNumber=0, likeNumber=92, createdTime=2012-04-12, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cff5000a3, moduleTitle=Nature：抗血管生成药物治疗癌症的局限性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cff5000a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545636, encodeId=bfa3154563626, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=综述：抗血管生成靶向药物与出血及血栓栓塞, objectType=article, longId=4139, objectId=bd28413958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd28413958, replyNumber=0, likeNumber=81, createdTime=2012-02-26, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd28413958, moduleTitle=综述：抗血管生成靶向药物与出血及血栓栓塞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd28413958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545635, encodeId=0ad81545635d0, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, objectTitle=抗血管生成靶向药物与出血及血栓栓塞, objectType=article, longId=3889, objectId=504b38890f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=504b38890f, replyNumber=0, likeNumber=74, createdTime=2012-02-08, rootId=0, userName=12498bd5m20暂无昵称, userId=608413807146, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=504b38890f, moduleTitle=抗血管生成靶向药物与出血及血栓栓塞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=504b38890f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗血管生成

2020-05-29

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-14

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-12

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

Biomaterials：研发基于高分子铜螯合剂的多功能纳米治疗体系用于联合抗血管生成与免疫疗法靶向治疗乳腺癌

2019-04-15

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？

2018-12-25

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

Gene & Cancer Sci：【重磅】盐酸安罗替尼抗血管生成机制详解

2018-04-05

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

【大咖来啰】抗血管生成新药安罗替尼崭露锋芒

2017-11-30

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

ANN ONCOL：FAK蛋白表达与结直肠癌抗血管生成治疗反应有关

2017-11-02

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

Front Mol Neurosci：研究发现抗血管生成的通路或可成为成胶质细胞瘤的新靶点

2017-10-23

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

【CSCO 2017】王宝成教授：抗血管生成治疗耐药的理解与对策

2017-10-02

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识（2016年版）

2016-12-08

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

PNAS：抗血管生成药物可显著改善肺结核的治疗

2015-02-05

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

Int J Cancer：抗血管生成药物多巴胺或可用于癌症治疗

2015-01-14

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

Nature：抗血管生成药物治疗癌症的局限性

2012-04-12

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

综述：抗血管生成靶向药物与出血及血栓栓塞

2012-02-26

12498bd5m20暂无昵称 (审核中...)

前往app查看评论内容

#抗血管生成#

抗血管生成靶向药物与出血及血栓栓塞

2012-02-08

科室
- - 订阅+
  - 更多科室
工具
服务